About Axios Biosciences
Axios Biosciences is a company based in Cambridge (United States) founded in 2009 by Douglas McMillin and Ashraf Haque. It operates as a B2B. Axios Biosciences operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Cambridge, United States
- Founders Douglas McMillin, Ashraf Haque
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$288.7 K (USD), Grant
Sep 09, 2013
-
Investors
HHS
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Axios Biosciences
Investors in Axios Biosciences
Axios Biosciences has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and MassChallenge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage entrepreneurs are accelerated through MassChallenge's program.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Axios Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axios Biosciences
Investment portfolio details for Axios Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Axios Biosciences
Detailed financials for Axios Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axios Biosciences Comparisons
Peer comparison for Axios Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Axios Biosciences
Axios Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of Axios Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axios Biosciences
Complete news archive for Axios Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axios Biosciences
Axios Biosciences was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Axios Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Axios Biosciences, led by Douglas McMillin as Co-Founder, President, Ashraf Haque as Co-Founder, specializes in advancing biotech innovations, drug development, oncology, and anti-cancer platforms. Creates innovative platforms for anti-cancer drug development. The team drives innovation, quality service, and sustainable practices to achieve excellence and client satisfaction.
Axios Biosciences's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Axios Biosciences has 2 investors. Key investors include HHS, and MassChallenge.